HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed...
Hence then, the article about akeso announced enrollment of first patient in phase 3 trial of cadonilimab for consolidation therapy after concurrent or sequential chemoradiotherapy in nsclc was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC )
Also on site :
- Trump shares shock video of migrant bludgeoning Florida woman to death (GRAPHIC)
- Immune Resetting: B-Cell Mediated & Beyond Summit 2026 Oral Presentation: Innovent Biologics Announces Pre-Clinical Results of IBI3055, a Tri-specific T Cell Engager Targeting Autoimmune Diseases
- Finn Wolfhard Told ‘Malcolm in the Middle’ Creator “F*ck Yeah” To Revival Cameo: “He’s Such A Big Fan”